Table 2 Pathway over-representation analysis (ORA) of the DEG.
Time of exposure | Biological function | Name pathway | p-value |
|---|---|---|---|
2 h | Signal Transduction | Olfactory receptor activity | 3.03E-09 |
Olfactory transduction | 4.73E-09 | ||
Olfactory Signalling Pathway | 8.72E-09 | ||
GPCR downstream Signalling | 6.47E-07 | ||
Signalling by GPCR | 1.60E-06 | ||
GPCRs, Class A Rhodopsin-like | 0.00518 | ||
Signal Transduction | 0.0125 | ||
Immune system | Staphylococcus aureus infection | 0.0113 | |
Dectin-2 family | 0.0125 | ||
Metabolism | Vitamin A and Carotenoid Metabolism | 0.0297 | |
Retinol metabolism | 0.0468 | ||
Transport | Cation-coupled Chloride cotransporters | 0.0125 | |
4 h | Signal Transduction | Olfactory Signalling Pathway | 1.57E-05 |
Olfactory receptor activity | 9.53E-05 | ||
Olfactory transduction | 9.53E-05 | ||
GPCR downstream Signalling | 0.000714 | ||
Signalling by GPCR | 0.000807 | ||
GPCR Signalling-G alpha i | 0.0223 | ||
GPCR Signalling-pertussis toxin | 0.0223 | ||
VEGF binds to VEGFR leading to receptor dimerization | 0.0223 | ||
VEGF ligand-receptor interactions | 0.0223 | ||
GPCR Signalling-cholera toxin | 0.0234 | ||
GPCR Signalling-G alpha s Epac and ERK | 0.0234 | ||
GPCR Signalling-G alpha q | 0.0234 | ||
VEGF and VEGFR Signalling network | 0.0234 | ||
Signal Transduction | 0.0234 | ||
GPCR Signalling-G alpha s PKA and ERK | 0.0234 | ||
Metabolism | Serotonin and melatonin biosynthesis | 0.0127 | |
Bile acid and bile salt metabolism | 0.029 | ||
Peptide hormone metabolism | 0.029 | ||
Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 0.029 | ||
Biogenic Amine Synthesis | 0.037 | ||
Metabolism of Angiotensinogen to Angiotensins | 0.0389 | ||
Primary bile acid biosynthesis | 0.0407 | ||
Amine-derived hormones | 0.044 | ||
Transport | Ligand-gated ion channel transport | 0.00701 | |
Transport of organic anions | 0.0234 | ||
Transmembrane transport of small molecules | 0.029 | ||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | 0.0389 | ||
Neuronal system | Serotonin and anxiety | 0.029 | |
Serotonergic synapse | 0.0407 | ||
Neuroactive ligand-receptor interaction | 0.0446 | ||
24 h | Signal Transduction | Gastrin-CREB Signal Transduction pathway via PKC and MAPK | 0.108 |
Peptide ligand-binding receptors | 0.108 | ||
Class A/1 (Rhodopsin-like receptors) | 0.108 | ||
G alpha (i) Signal Transduction events | 0.128 | ||
Immune system | Negative regulation of MAPK pathway | 0.131 | |
Metabolism | Glucocorticoid Receptor Pathway | 0.00221 | |
Glycine, serine, alanine and threonine metabolism | 0.0207 | ||
Creatine metabolism | 0.108 | ||
Prostaglandin Synthesis and Regulation | 0.108 | ||
Metabolism of polyamines | 0.128 | ||
Transport | Bile salt and organic anion SLC transporters | 0.128 | |
Neuronal system | TarBasePathway | 0.128 | |
HCN channels | 0.03 | ||
Cancer | Photodynamic therapy-induced HIF-1 survival Signalling | 0.128 | |
Gene expression (Transcription) | TP53 Regulates Transcription of Cell Cycle Genes | 0.128 | |
Developmental biology | Endoderm Differentiation | 0.128 | |
Developmental Biology | 0.108 | ||
Haemostasis | Hemostasis | 0.0382 |
